Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 12;43(5):823-840.e18.
doi: 10.1016/j.ccell.2025.03.003. Epub 2025 Mar 27.

Translation dysregulation in cancer as a source for targetable antigens

Affiliations

Translation dysregulation in cancer as a source for targetable antigens

Chen Weller et al. Cancer Cell. .

Abstract

Aberrant peptides presented by major histocompatibility complex (MHC) molecules are targets for tumor eradication, as these peptides can be recognized as foreign by T cells. Protein synthesis in malignant cells is dysregulated, which may result in the generation and presentation of aberrant peptides that can be exploited for T cell-based therapies. To investigate the role of translational dysregulation in immunological tumor control, we disrupt translation fidelity by deleting tRNA wybutosine (yW)-synthesizing protein 2 (TYW2) in tumor cells and characterize the downstream impact on translation fidelity and immunogenicity using immunopeptidomics, genomics, and functional assays. These analyses reveal that TYW2 knockout (KO) cells generate immunogenic out-of-frame peptides. Furthermore, Tyw2 loss increases tumor immunogenicity and leads to anti-programmed cell death 1 (PD-1) checkpoint blockade sensitivity in vivo. Importantly, reduced TYW2 expression is associated with increased response to checkpoint blockade in patients. Together, we demonstrate that defects in translation fidelity drive tumor immunogenicity and may be leveraged for cancer immunotherapy.

Keywords: cancer immunopeptidome; immune checkpoint blockade; neoantigens; non-canonical peptides; translation fidelity.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Y. Samuels, O.B., and C.W. hold patents related to TYW2. C.S.M. holds patents related to MULTI-seq. A.T.S. is a founder of Immunai, Cartography Biosciences, Santa Ana Biosciences, and Prox Biosciences, an advisor to 10× Genomics and Wing Venture Capital, and receives research funding from Merck Research Laboratories and Astellas Pharma. E.R. is a divested co-founder of Pangea Biomed and is a non-paid member of the scientific advisory boards of Pangea Biomed and GSK oncology.

References

    1. Tran E, Robbins PF, and Rosenberg SA (2017). 'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18, 255–262. 10.1038/ni.3682. - DOI - PMC - PubMed
    1. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, et al. (2014). Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515, 577–581. 10.1038/nature13988. - DOI - PMC - PubMed
    1. Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD, Paria BC, Malekzadeh P, Jia L, Yossef R, Langhan MM, et al. (2018). T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. Clin Cancer Res 24, 5562–5573. 10.1158/1078-0432.CCR-18-0573. - DOI - PMC - PubMed
    1. Blass E, and Ott PA (2021). Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol 18, 215–229. 10.1038/s41571-020-00460-2. - DOI - PMC - PubMed
    1. Fritsch EF, Burkhardt UE, Hacohen N, and Wu CJ (2020). Personal Neoantigen Cancer Vaccines: A Road Not Fully Paved. Cancer Immunol Res 8, 1465–1469. 10.1158/2326-6066.CIR-20-0526. - DOI - PMC - PubMed

Substances

LinkOut - more resources